Shares of Achillion Pharmaceuticals Inc. (ACHN) tanked 22 percent in after-hours trade on Monday, as the U.S. Food and Drug Administration placed on clinical hold its hepatitis C drug, sovaprevir, following elevated liver enzymes during a Phase 1 drug-drug interaction study with ritonavir-boosted atazanavir.
Meanwhile, the FDA has allowed on continued enrollment and treatment of patients in the Phase 2 -007 clinical trial evaluating 12-weeks of sovaprevir in combination with ACH-3102 and ribavirin for patients with treatment-naive genotype 1 hepatitis C viral infection.
In the Phase 1 drug-drug interaction study that evaluated the effects of concomitant administration of sovaprevir with ritonavir-boosted atazanavir, Achillion found unexpected elevations in ALT liver enzymes in multiple subjects and notified the FDA.
"Preliminary pharmacokinetic results indicate a metabolic interaction whereby plasma concentrations of both atazanavir and sovaprevir were substantially increased upon co-administration," the company said. Such elevations were not seen in any other drug-drug interaction studies completed with sovaprevir, the company noted.
The FDA has asked for study reports from two drug-drug interaction studies and an integrated safety analysis of on-going sovaprevir trials, each of which Achillion expects to provide within six weeks.
As for the ongoing -007 Phase 2 clinical trial, Achillion is treating patients in the first segment and plans to release interim trial results in the third and fourth quarters.
Hepatitis C is an infectious disease affecting mainly the liver, caused by the hepatitis C virus. The disease is spread mainly by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment and transfusions. It is estimated that over 170 million people are infected with HCV worldwide.
Sovaprevir is a potent inhibitor of HCV NS3 protease which has the potential to be a best-in-class protease inhibitor for the treatment of chronic HCV infection.
Achillon closed Monday at $8.36, up 2.20%, on a volume of 851 thousand shares. In after hours, the stock dropped $1.88 or 22.49% at $6.48.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.